Stereotactic body radiotherapy for organ-confined prostate cancer. - Test2 - elhamkhani - TriplyDB

Stereotactic body radiotherapy for organ-confined prostate cancer.

Stereotactic body radiotherapy for organ-confined prostate cancer.

http://www.wikidata.org/entity/Q33528163

about

The RSSearch™ Registry: patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy A Phase II Trial of Stereotactic Ablative Body Radiotherapy for Low-Risk Prostate Cancer Using a Non-Robotic Linear Accelerator and Real-Time Target Tracking: Report of Toxicity, Quality of Life, and Disease Control Outcomes with 5-Year Minimum Foll Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results Proctitis following stereotactic body radiation therapy for prostate cancer Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer Multi-institutional registry for prostate cancer radiosurgery: a prospective observational clinical trial.A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy.Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer Symptomatic and quality-of-life outcomes after treatment for clinically localised prostate cancer: a systematic review.Sexual, irritative, and voiding outcomes, following stereotactic body radiation therapy for prostate cancer.Laminin receptor specific therapeutic gold nanoparticles (198AuNP-EGCg) show efficacy in treating prostate cancer.Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer.Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer.Hypofractionated external-beam radiotherapy for prostate cancer.Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer.The CyberKnife Robotic Radiosurgery System in 2010.Stereotactic body radiation therapy for prostate cancer.Single institution's dosimetry and IGRT analysis of prostate SBRT.From radiobiology to technology: what is changing in radiotherapy for prostate cancer.The tolerance of gastrointestinal organs to stereotactic body radiation therapy: what do we know so far?Stereotactic body radiotherapy for primary prostate cancer: a systematic review.Progress and controversies: Radiation therapy for prostate cancer.Hypofractioned radiotherapy in prostate cancer: is it the next step?The evolution of rectal and urinary toxicity and immune response in prostate cancer patients treated with two three-dimensional conformal radiotherapy techniques.Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).Hypofractionated radiotherapy for prostate cancer.Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer SBRT and extreme hypofractionation: A new era in prostate cancer treatments?Hypofractionated stereotactic body radiotherapy for localized prostate cancer - first Nordic clinical experience.A survey of stereotactic body radiotherapy use in the United States CyberKnife radiosurgery for prostate cancer.Image-guided hypofractionated proton beam therapy for low-risk prostate cancer: Analysis of quality of life and toxicity, PCG GU 002.Stereotactic body radiation therapy for the primary treatment of localized prostate cancer.Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes.Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer.Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years.Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.Stereotactic Body Radiation Therapy for Low- and Low-Intermediate-Risk Prostate Cancer: Is there a Dose Effect?Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer.

P2860

Q30443893-3CADA1D4-4D53-4612-8281-1EF14E94B18B Q34510485-9B8A009C-8EEC-4FDA-A922-CF4998209540 Q34660610-035E8C71-FE17-42BD-9F8C-EC09F1E8ACC7 Q34748877-5FFA4440-AC66-4364-9E64-4F532AAC87C8 Q34871906-89DA64B0-13B7-4E92-B865-E9386F2E6105 Q34999092-8E71E297-B759-4FE0-BE39-8E3F9D0E8214 Q35019637-04CD7199-C8CD-4D97-AC4D-774A5B92E58B Q35111775-E077F44E-B957-446B-B976-6C86D1EBBABE Q35992097-C9130A79-795D-43F2-8090-CE14D86A3D5F Q36009944-7117969F-2B1B-4C23-AA7E-CC0924A251E0 Q36140458-422DF4BB-C4CF-4A6F-A5B8-974E77762384 Q36174829-F42B2413-50DD-4ED4-8680-95D4F38664F1 Q36604355-EA9E2886-1BAC-4EED-B378-075D3318F332 Q36711751-B073FEF5-C090-4B61-918C-6A9A91B7C329 Q36722591-0EEAA67F-BE48-4A85-9070-37041A826103 Q37116581-440A5F71-8235-46CE-9AC4-1FB928EB5064 Q37785075-1518024C-76D1-4CB8-ADDB-D833D93C10C5 Q37932543-264FAC7A-5BEA-4563-B6C3-697634874CB9 Q38137328-F81E982A-5373-4967-8CC6-CD917C93FA24 Q38191990-25F4A263-215A-4F04-825D-0984D291FD04 Q38225135-DC3DD2CE-5AE4-419A-97C5-87ED3EFC66C1 Q38243077-02CBC942-3752-49CF-A7BD-83BD7FE7BEE0 Q38252429-C73657CF-1F16-4402-9458-C104F59EC02B Q38264783-B08428EA-5BE6-45A8-BA3E-C6C2B75808E7 Q38266168-06AA56B1-735E-4DE7-819E-D0024A3219F8 Q38268325-CD82FB4A-6AB2-4A1D-BF55-F2B45ADFCFE7 Q38283897-27C12968-7C0A-485F-84DB-CF56E47E1020 Q38550590-02A86FDA-C552-4528-9B18-BC26DB7EAA57 Q38677018-29AC8192-9305-494D-BE51-B279EECAC153 Q38780363-6DC0E82C-4E44-40E0-9C25-1A4B6A47F6A9 Q39771088-FA7EEF9E-75FC-454E-A0A2-332067963E98 Q39841215-C4A9AB99-ED10-4C2F-88D9-50D1B6B0053A Q40959958-8054784E-B484-4B78-A603-8780BDAE5CA7 Q41259152-316F16B3-B176-4A71-B5CA-6FC3A0A08CE2 Q41775778-918F9205-4F6A-4B78-95A2-B5C9FA5379C6 Q41833334-E7D97242-65F8-4277-B132-416679AE317A Q41895986-352282F2-90BA-4ACB-BC0A-EC4D9BAE6E6D Q41952611-A2078F03-74FA-4197-B55D-FBE90E04AA0A Q41979463-BCEC15A9-DC2E-4AA7-B6C2-2735A01EF990 Q41985869-1CEE025A-C3BB-40B1-95FA-054FA8DDAD2B

P2860

Stereotactic body radiotherapy for organ-confined prostate cancer.

http://www.wikidata.org/entity/Q33528163

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Stereotactic body radiotherapy for organ-confined prostate cancer.

@ast

Stereotactic body radiotherapy for organ-confined prostate cancer.

@en

Stereotactic body radiotherapy for organ-confined prostate cancer.

@nl

type

label

Stereotactic body radiotherapy for organ-confined prostate cancer.

@ast

Stereotactic body radiotherapy for organ-confined prostate cancer.

@en

Stereotactic body radiotherapy for organ-confined prostate cancer.

@nl

prefLabel

Stereotactic body radiotherapy for organ-confined prostate cancer.

@ast

Stereotactic body radiotherapy for organ-confined prostate cancer.

@en

Stereotactic body radiotherapy for organ-confined prostate cancer.

@nl

P1433

Q33528163-DD897F91-5C93-4309-9A1E-F5DD4C429F0F

P1476

Q33528163-4D0467F4-7F6A-4C19-8A66-DF0E60D64BEB

P2093

Q33528163-22BEA5E7-88FD-4D8C-BF8D-C5F036DD48AA

Q33528163-3E726D66-BE64-4BDA-BF10-0BB1305D37E2

Q33528163-7802521B-37AB-43F9-82D0-6F9A918A5B55

Q33528163-E0BBE54D-18FD-4B90-BF07-D38184B8A9F5

Q33528163-F1A4FA5F-9116-446B-8B7C-4E3C2E36F503

P2860

Q33528163-02422B22-2210-4573-8B2B-E9DE0E091F35

Q33528163-13BFA3CD-B505-42FF-B2EA-1F770213F138

Q33528163-15C681FB-908A-43BE-A758-267F614DC227

Q33528163-36F5C418-4863-407A-A33F-7F6B8992FCCC

Q33528163-4938E9D4-19AD-43E4-BE64-4D80E2F0D4F3

Q33528163-500E01D3-B82E-465D-B817-502323430187

Q33528163-51B09868-3B1F-46C5-A7FF-53BA03EFFBA8

Q33528163-5839E2CA-8008-4621-8538-504E631135B9

Q33528163-6CAB16C0-CEF2-4EC5-A3E1-10FBAC6733DE

Q33528163-81DD4289-5B99-4BF7-A9B4-B0A99550E0FD

P2888

Q33528163-02542C45-8261-4806-96DF-F90D569683A2

P304

Q33528163-19B71451-82DF-4C88-8766-31E04D2417CF

P31

Q33528163-B7C1E31E-8737-40C4-8EC0-CB2BDA071414

P356

Q33528163-AAB64373-C1AA-4E70-AF37-8F564A927AA2

P478

Q33528163-D11530B6-0740-46A9-A5E4-D4134869A01C

P577

Q33528163-B3D9C48E-82B9-443B-830B-674EF613FA27

P5875

Q33528163-5DC1E881-1816-49EF-BF04-4E5A0A27DF62

P6179

Q33528163-D1592000-694F-4095-A851-702B5ED97215

P698

Q33528163-0587A0F7-384C-4E5C-BF62-674DE9D2278C

P921

Q33528163-7265D4B5-9346-438A-B98F-14BD87FEB161

P932

Q33528163-820BEBBE-EEA8-46D6-A733-BAB0887C7885

P356

P1433

P1476

Stereotactic body radiotherapy for organ-confined prostate cancer.

@en

P2093

Alan J Katz

http://www.w3.org/2001/XMLSchema#string

Ferdinand Diblasio

http://www.w3.org/2001/XMLSchema#string

Matthew Witten

http://www.w3.org/2001/XMLSchema#string

Michael Santoro

http://www.w3.org/2001/XMLSchema#string

Richard Ashley

http://www.w3.org/2001/XMLSchema#string

P2860

Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma.

High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.

Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score.

Image-guided radiosurgical ablation of intra- and extra-cranial lesions.

Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?

Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial.

Hypogonadism following prostate-bed radiation therapy for prostate carcinoma.

P2888

P304

1

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2490-10-1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41397520

http://www.w3.org/2001/XMLSchema#string

P6179

1007290992

http://www.w3.org/2001/XMLSchema#string

P698

20122161

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

2831888

http://www.w3.org/2001/XMLSchema#string